Nutlin 3 - an overview | ScienceDirect Topics
Idasanutlin (RG-7388) | ≥99%(HPLC) | Selleck | Mdm2 inhibitor
Frontiers | Restoring p53 Function in Head and Neck Squamous Cell Carcinoma to Improve Treatments | Oncology
Nutlin-3, A p53-Mdm2 Antagonist for Nasopharyngeal Carcinoma Treatment | Bentham Science
Nutlin 3 - an overview | ScienceDirect Topics
Nutlin-3 | ≥99%(HPLC) | Selleck | Mdm2 antagonist
Oridonin synergizes with Nutlin-3 in inhibition of cell viability of OS... | Download Scientific Diagram
The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276 | Cellular & Molecular Biology Letters | Full Text
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy | PNAS
Nutlin-3 | CAS 548472-68-0 | AbMole BioScience | Nutlin-3 Price
Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity
p53 programmes plough on
Nutlin-3 sensitizes nasopharyngeal carcinoma cells to cisplatin-induced cytotoxicity
Inhibition of MDM2 via Nutlin-3A: A Potential Therapeutic Approach for Pleural Mesotheliomas with MDM2-Induced Inactivation of Wild-Type P53
Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy | PNAS
Structurally diverse MDM2–p53 antagonists act as modulators of MDR-1 function in neuroblastoma | British Journal of Cancer
Frontiers | Clinical Overview of MDM2/X-Targeted Therapies | Oncology
Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells | Cell Death & Disease
MDM2 antagonists as a novel treatment option for acute myeloid leukemi | OTT
The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276 | Cellular & Molecular Biology Letters | Full Text
Extended treatment with Nutlin-3 results in reduced sensitivity without... | Download Scientific Diagram
